UMIN-CTR Clinical Trial
| Unique ID issued by UMIN | UMIN000032193 |
|---|---|
| Receipt number | R000036705 |
| Scientific Title | Efficacy and safety of combination therapy of corticosteroid and tacrolimus for patients with anti-melanoma differentiation antigen 5 antibody-positive dermatomyositis-associated interstitial lung disease: a prospective multicenter clinical trial |
| Date of disclosure of the study information | 2018/04/13 |
| Last modified on | 2024/09/15 21:13:42 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
Efficacy and safety of combination therapy of corticosteroid and tacrolimus for patients with anti-melanoma differentiation antigen 5 antibody-positive dermatomyositis-associated interstitial lung disease: a prospective multicenter clinical trial
Acronym
Combination therapy of corticosteroid and tacrolimus for anti-MDA5 antibody-positive DM-ILD
Scientific Title
Efficacy and safety of combination therapy of corticosteroid and tacrolimus for patients with anti-melanoma differentiation antigen 5 antibody-positive dermatomyositis-associated interstitial lung disease: a prospective multicenter clinical trial
Scientific Title:Acronym
Combination therapy of corticosteroid and tacrolimus for anti-MDA5 antibody-positive DM-ILD
Region
| Japan |
Condition
Condition
anti-melanoma differentiation antigen 5 antibody-positive dermatomyositis (DM)/clinically amyopathic dermatomyositis (CADM)-associated interstitial lung disease
Classification by specialty
| Pneumology | Clinical immunology |
Classification by malignancy
Others
Genomic information
NO
Objectives
Narrative objectives1
To evaluate the efficacy and safety of combination therapy of corticosteroid and tacrolimus for patients with anti-MDA5 antibody-positive dermatomyositis (DM)/clinically amyopathic dermatomyositis (CADM)-associated interstitial lung disease (ILD) without poor prognostic factors.
To investigate the clinical course and prognosis for patients with anti-MDA5 antibody-positive DM/CADM-ILD with poor prognostic factors.
When patients have any or some of the following factors, they were defined as "with poor prognostic factor". When patients have none of the following factors, they were defined as "without poor prognostic factor".
1, Rapidly progressive interstitial lung disease
2, Serum ferritin level is more than 800 ng/ml
3, PaO2 < 65 Torr at room air
Basic objectives2
Efficacy
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase
Assessment
Primary outcomes
Progression free survival and progression free survival rate at 12 month in patients with anti-MDA5 antibody-positive DM/CADM-ILD without poor prognostic factors
Key secondary outcomes
"The patients without poor prognostic factor"
Overall survival and overall survival rate at 12 month
Change in FVC, FEV1, DLCO, PaO2, SPO2, KL-6, SP-D, anti-MDA5 antibody titer, Chest HRCT findings
Incidence of adverse events
"The patients with poor prognostic factor"
Overall survival and overall survival rate at 12 month.
Base
Study type
Interventional
Study design
Basic design
Single arm
Randomization
Non-randomized
Randomization unit
Blinding
Open -no one is blinded
Control
Uncontrolled
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment
Intervention
No. of arms
1
Purpose of intervention
Treatment
Type of intervention
| Medicine |
Interventions/Control_1
Patients without poor prognostic factors:
combination therapy of corticosteroid (prednisolone) and tacrolimus for 12 months
Initial dose of oral prednisolone is 0.7 - 1mg/kg/day (Maximum dose of prednisolone is 60mg/body/day). Intravenous methylprednisolone pulse therapy (0.5 - 1g/day for 3 days) is permitted according to the initial disease activity.
After 4 weeks of initial treatment, prednisolone is tapered by approximately 10 to 20% every 2 to 4 weeks and continued at dose of 0.125 mg/kg/day or more in the study period (12 months).
Tacrolimus is administered orally at initial dose of 0.075 mg/kg/day (twice daily) and adjusted over time to maintain a whole-blood trough level of 5 - 10 ng/ml.
For patients with poor prognostic factors, attending physician can chose any treatments (e.g. corticosteroid, immunosuppressant, IVIG). The patients were followed up for 12 months.
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| 20 | years-old | <= |
Age-upper limit
| 80 | years-old | > |
Gender
Male and Female
Key inclusion criteria
Patients with DM/CADM-ILD who are positive for serum anti-MDA5 antibodies and have not previously received treatment for DM/CADM-ILD.
Key exclusion criteria
Patients who meet the following criteria are excluded from this study:
(1) Patients who require systemic high dose corticosteroid, immunosuppressants, intravenous immunoglobulin therapy, plasma exchange, or biologic agents for a disease other than DM/CADM-ILD at the registration
(2) Patients with contraindication of prednisolone or tacrolimus
(3) Patients with a serious comorbidity (e.g. advanced malignancy, imminent aortic aneurysm, and Liver cirrhosis)
(4) Patients who are judged unqualified for this study by attending physician
Target sample size
40
Research contact person
Name of lead principal investigator
| 1st name | Takafumi |
| Middle name | |
| Last name | Suda |
Organization
Hamamatsu University School of Medicine
Division name
Second Division, Department of Internal Medicine
Zip code
431-3192
Address
1-20-1 Handayama Higashi-ku, Hamamatsu, 431-3192 Japan
TEL
0534352263
suda@hama-med.ac.jp
Public contact
Name of contact person
| 1st name | Tomoyuki |
| Middle name | |
| Last name | Fujisawa |
Organization
Hamamatsu University School of Medicine
Division name
Second Division, Department of Internal Medicine
Zip code
431-3192
Address
1-20-1 Handayama Higashi-ku, Hamamatsu, 431-3192 Japan
TEL
0534352263
Homepage URL
fujisawa@hama-med.ac.jp
Sponsor or person
Institute
Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine
Institute
Department
Personal name
Funding Source
Organization
Hamamatsu University School of Medicine
Organization
Division
Category of Funding Organization
Self funding
Nationality of Funding Organization
Other related organizations
Co-sponsor
Name of secondary funder(s)
IRB Contact (For public release)
Organization
the Ethical Committee of Hamamatsu University School of Medicine
Address
1-20-1 Handayama Chuo-ku, Hamamatsu, 431-3192 Japan
Tel
053-435-2680
rinri@hama-med.ac.jp
Secondary IDs
Secondary IDs
NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
浜松医科大学、磐田市立総合病院、国立病院機構天竜病院、JA静岡厚生連 遠州病院、静岡県立総合病院、静岡済生会総合病院、静岡市立静岡病院、静岡市立清水病院、静岡赤十字病院、聖隷浜松病院、聖隷三方原病院、浜松労災病院、浜松医療センター、藤枝市立総合病院
Other administrative information
Date of disclosure of the study information
| 2018 | Year | 04 | Month | 13 | Day |
Related information
URL releasing protocol
Publication of results
Unpublished
Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
Open public recruiting
Date of protocol fixation
| 2018 | Year | 03 | Month | 16 | Day |
Date of IRB
Anticipated trial start date
| 2018 | Year | 04 | Month | 11 | Day |
Last follow-up date
Date of closure to data entry
Date trial data considered complete
Date analysis concluded
Other
Other related information
Management information
Registered date
| 2018 | Year | 04 | Month | 11 | Day |
Last modified on
| 2024 | Year | 09 | Month | 15 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000036705
